Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Proceedings of the 8th Global Arthritis Research Network (GARN) Meeting and 1st Bio-Rheumatology International Congress (BRIC)

Poster presentation

MiRs in RA: possible biomarkers and therapeutic targets

Maria Filkova1*, Caroline Ospelt1, Joanna Stanczyk1, Serena Vettori1, Ladislav Senolt2, Mojca Frank1, Christoph Kolling3, Beat A Michel1, Renate E Gay1, Steffen Gay1 and Astrid Jüngel1

  • * Corresponding author: Maria Filkova

Author Affiliations

1 Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

2 Institute of Rheumatology, Department of Experimental Rheumatology of the 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

3 Schultess Clinic, Zurich, Switzerland

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14(Suppl 1):P14  doi:10.1186/ar3615

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S1/P14


Published:9 February 2012

© 2012 Filkova et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and objective

New concepts of therapy highlight an early use of effective treatment to prevent further joint damage in RA. Altered expression of epigenetic marks like miRs offers us the possibility to develop new diagnostic tools and novel therapeutic targets.

We found miR-146, -155 and -203 to be upregulated in rheumatoid arthritis (RA) synovial fibroblasts (SF) compared to osteoarthritis (OA) SF [1,2]. Based on the comprehensive analysis of the expression of 260 miRs we found miR-196a to be one of the most downregulated miRs in RASF. In peripheral blood mononuclear cells, miR-132 and -223 are upregulated in established RA compared with healthy controls (HC) [3,4].

Our aim was to analyze miRs as potential systemic markers in early stages of the disease and to find new miRs locally at the site of inflammation that play a role in the pathogenesis of RA.

Methods

MiRs from sera of patients with treatment naïve early RA (ERA), with treated established RA and HC were isolated by phenol-chloroform extraction. TaqMan Low Density Array was used to analyze the expression of 260 miRs in RASF and OASF. MiR-196a expression was further analyzed in additional RASF and OASF, RA and OA synovial tissues. TaqMan RealTime-PCR was used for quantification of miRs and functional experiments (MTT, scratch assay, AnnexinV FACS) were performed following transfection with pre-miR or miR-196a inhibitor.

Results

In sera of patients with ERA, the expression of miR-146a was lower than in both HC (p < 0.05) and established RA sera (p < 0.001) while miR-155, 132, -203 and -223 showed no differences.

In RASF, the expression of miR-196a is significantly lower than in OASF (p < 0.0001) as well as in RA synovial tissues compared with OA (p = 0.01). RASF transfection with pre-miR/miR-196a inhibitor resulted in down/upregulation of predicted targets HOXC8 and ANXA1. Pre-miR-196a suppressed cell proliferation (27.5%) and migration (41.5%) and induced apoptosis (54.1%) while miR-196a inhibitor enhanced both proliferation (81.9%) and migration (231%) and reduced apoptosis (52.3%) in RASF.

Conclusion

In contrast to established RA synovial fibroblasts where an increased expression of miR-146a was reported, our data showed that in early arthritis sera miR-146a is significantly downregulated and might characterize an early clinical stage of the disease. The low expression of miR-196a in both RA synovial tissue and in isolated SF contributes to the aggressive and invasive phenotype of RASF by modifying proliferation, migration and apoptosis with an impact on the pathogenesis of RA.

Acknowledgements

This work was supported by IAR-EPALINGES, FP7 Masterswitch, MH CR- grant project No.10065-4 and ARTICULUM fellowship.

References

  1. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D: Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation.

    Arthritis Rheum 2011, 63:373-81. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis.

    Arthritis Rheum 2008, 58:1001-9. PubMed Abstract | Publisher Full Text OpenURL

  3. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients.

    Arthritis Res Ther 2008, 10:R101. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  4. Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G: miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis.

    Hum Immunol 2010, 71:206-11. PubMed Abstract | Publisher Full Text OpenURL